A Phase 3 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Placebo in Sinusitis, sponsored by Bayer. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-26.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Sinusitis with a site in United States — 6 open to participants now, 12 under way, none of them phase 3. Sinusitis · United States.
Among the 129 studies in Sinusitis with a site in United States, this one is the 8th largest by enrollment of the 103 interventional ones that give a count, is one of 7 that started in 2005, is one of 12 in phase 3, and was the 20th registered.
256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.
Browse Sinusitis studies →6 of the 129 studies in Sinusitis with a site in United States are open now. Recruiting first, the newest first:
Nader Shaikh · Sites in United States
Ages 2–12
Medical University of South Carolina · Sites in United States
Ages 18+
Geisinger Clinic · Sites in United States
Ages 65–100
Daniel Merenstein · Sites in United States
Ages 18–75
QHSLab, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 14 · Phase 4 23
First in 1999; this study’s year is marked. 7 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 374 is above the median of 60 across 196 interventional studies indexed under Sinusitis.
Median enrollment 44 across the 103 interventional studies, 100 across the 25 observational. Of the 100 that completed or were terminated, 52 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 129 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 4 studies filed under Sinusitis — fewer than ten, so there is no comparison to draw.
3 of the studies in Sinusitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03256773University of Alabama at BirminghamHigh Resolution Micro OCT Imaging | 2026-12-31 |
| NCT06495021Geisinger ClinicHow OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care. | 2026-12-31 |
| NCT06272123Thomas Jefferson UniversityEndotypic Stability in CRS | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 129 studies in Sinusitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of acute bacterial sinusitis, therefore in this study Avelox is considered an investigational drug. In this study Avelox will be compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all the following criteria at the time of enrollment:
Clinical diagnosis of acute bacterial sinusitis with signs and symptoms present for = 7 days but \< 28 days as defined by A), radiographic, and B) clinical criteria, as follows:
Clinical Criteria: The presence of two major symptoms, or the presence of at least one major and one minor symptom as defined in the list below:
Exclusion Criteria:
Subjects with one or more of the following criteria will not be eligible for this study:
Moxifloxacin 400mg once daily for 5 days
Drug: Moxifloxacin (Avelox, BAY12-8039)
Matching placebo for 5 days
Drug: Placebo
Moxifloxacin - 400 mg once a day for 5 days
Placebo - 380 mg Microcrystalline Cellulose
Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))
The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.
Time frame: At 'Test-of-Cure' (TOC), Day 1-5 after end of treatment
Treatment Day When Patients Reached Symptom Improvement as Measured by Patient Reported Data, Using Last Observation Carried Forward (LOCF) Approach
The Sino-Nasal Outcome Test (SNOT-16) was used to assess subject-reported time to symptom improvement. Improvement was defined as a decrease of at least 14 units on the test. This difference is the smallest difference that has been identified as beneficial to subjects.
Time frame: Daily until 'Test-Of-Cure' (Day 1-5 after end of treatment)
Treatment Day When Patients Returned to Normal Activities as Measured by Patient Reported Data, Using LOCF Approach
The Activity Impairment Assessment (AIA) questionnaire was used to assess activity impairment at baseline and time to return to normal activities. The AIA was administered prior to first dose, every 24 hours during treatment, and at the TOC visit. Improvement in the AIA total score was defined as a decrease of at least 3 units.
Time frame: Daily until 'Test-Of-Cure' (Day 1-5 after end of treatment)
Percentage of Subjects With Clinical Improvement During Therapy
A secondary efficacy variable was clinical response (CR) at the During Therapy visit at day 3 or 4 of treatment. CR was rated as improvement, cure, failure, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.
Time frame: Day 3 of treatment
Percentage of Subjects With Continued Clinical Cure During Long-Term Follow-Up
A secondary efficacy variable was clinical response (CR) at the Follow-up visit 17-21 days following the start of treatment. CR was rated as continued cure, failure/relapse, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.
Time frame: Day 12 to 26 after end of treatment
Percentage of Subjects With Clinical Cure (Per Protocol Population (PP))
The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.
Time frame: At 'Test-of-Cure', Day 1-5 after end of treatment
The study was conducted at 37 investigative centers in the United States from January 2005 to March 2008.
| Milestone | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Started | 251 | 123 |
| Completed | 222 | 101 |
| Not completed | 29 | 22 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lack of efficacy | 21 | 20 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Milestone | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Started | 222 | 101 |
| Completed | 221 | 99 |
| Not completed | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.
| Percentage of subjects | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Success (Clinical Cure) | 78.1 | 66.7 |
| Failure | 19.2 | 33.3 |
| Indeterminate | 2.7 | 0 |
| Complete resolution | 12.3 | 11.1 |
| Improvement | 65.8 | 55.6 |
The Sino-Nasal Outcome Test (SNOT-16) was used to assess subject-reported time to symptom improvement. Improvement was defined as a decrease of at least 14 units on the test. This difference is the smallest difference that has been identified as beneficial to subjects.
| participants | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Day 2 | 14 | 7 |
| Day 3 | 26 | 10 |
| Day 4 | 31 | 13 |
| Day 5 | 39 | 16 |
| Test-Of-Cure | 43 | 19 |
The Activity Impairment Assessment (AIA) questionnaire was used to assess activity impairment at baseline and time to return to normal activities. The AIA was administered prior to first dose, every 24 hours during treatment, and at the TOC visit. Improvement in the AIA total score was defined as a decrease of at least 3 units.
| participants | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Day 2 | 22 | 15 |
| Day 3 | 31 | 17 |
| Day 4 | 35 | 17 |
| Day 5 | 37 | 19 |
| Test-Of-Cure | 42 | 22 |
A secondary efficacy variable was clinical response (CR) at the During Therapy visit at day 3 or 4 of treatment. CR was rated as improvement, cure, failure, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.
| Percentage of subjects | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Improvement | 84.9 | 73.3 |
| Indeterminate | 4.1 | 4.4 |
| Missing | 11.0 | 22.2 |
A secondary efficacy variable was clinical response (CR) at the Follow-up visit 17-21 days following the start of treatment. CR was rated as continued cure, failure/relapse, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.
| Percentage of subjects | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Combined Clinical Cure | 73.9 | 57.7 |
| Clinical Failure / Relapse | 21.9 | 40.0 |
| Missing | 4.1 | 2.2 |
The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.
| Percentage of subjects | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Success | 82.3 | 66.7 |
| Failure | 17.7 | 33.3 |
| Indeterminate | 0 | 0 |
| Complete resolution | 11.3 | 9.5 |
| Improvement | 71.0 | 57.1 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moxifloxacin 400 mg | — | 1/251 (0.4%) | 49/251 (19.5%) |
| Placebo | — | 1/123 (0.8%) | 23/123 (18.7%) |
| Event | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| HypertensionVascular disorders | 0/251 | 1/123 |
| PneumoniaInfections and infestations | 1/251 | 0/123 |
| Event | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Procedural PainInjury, poisoning and procedural complications | 6/251 | 6/123 |
| NauseaGastrointestinal disorders | 11/251 | 2/123 |
| HeadacheNervous system disorders | 11/251 | 4/123 |
| DizzinessNervous system disorders | 9/251 | 1/123 |
| InsomniaPsychiatric disorders | 2/251 | 4/123 |
| DiarrhoeaGastrointestinal disorders | 5/251 | 3/123 |
| VomitingGastrointestinal disorders | 3/251 | 3/123 |
| Sinus headacheNervous system disorders | 6/251 | 2/123 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 6/251 | 2/123 |
| Age Continuous(years) | Moxifloxacin 400 mg | Placebo | Total |
|---|---|---|---|
| Mean | 40.1 ± 13.8 | 40.3 ± 13.0 | 40.2 ± 13.5 |
| Sex: Female, Male(Participants) | Moxifloxacin 400 mg | Placebo | Total |
|---|---|---|---|
| Female | 165 | 80 | 245 |
| Male | 86 | 43 | 129 |
| Causative Organisms Isolated from Pretreatment Specimens at Study Entry(participants) | Moxifloxacin 400 mg | Placebo | Total |
|---|---|---|---|
| Streptococcus pneumoniae | 32 | 13 | 45 |
| Moraxella catarrhalis | 7 | 12 | 19 |
| Haemophilus influenzae | 28 | 15 | 43 |
| Streptococcus pyogenes | 2 | 2 | 4 |
| Staphylococcus aureus | 11 | 5 | 16 |
| Non causative pathogene | 66 | 32 | 98 |
| No pathogene growth | 109 | 45 | 154 |
| Location of infection(participants) | Moxifloxacin 400 mg | Placebo | Total |
|---|---|---|---|
| Left | 82 | 37 | 119 |
| Right | 94 | 46 | 140 |
| Bilateral | 75 | 40 | 115 |
| Severity of infection(participants) | Moxifloxacin 400 mg | Placebo | Total |
|---|---|---|---|
| Moderate | 153 | 72 | 225 |
| Severe | 90 | 49 | 139 |
| Mild | 8 | 2 | 10 |
| Duration of infection(days) | Moxifloxacin 400 mg | Placebo | Total |
|---|---|---|---|
| Mean | 13.2 ± 5.4 | 12.7 ± 4.7 | 13.0 ± 5.1 |
The record gives a start of Jan 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin